Pooled evidence suggested that topical anaesthetic creams ( TAs ) , tramadol , selective serotonin reuptake inhibitors ( SSRIs ) , and phosphodiesterase type 5 inhibitors ( PDE5is ) are more effective at prolonging IELT comparing with placebo .
Conclusions We recommend the initial use of dapoxetine 30 mg OD for PE because it has been tested in largest and better design ed clinical trials rather than it is more effective than the other drugs studied .
TAs and tramadol 50 mg OD can be used as a viable alternative to oral treatment with SSRIs .
PDE5is combined with SSRIs are more effective than SSRIs monotherapy but are also associated with more side effects .
Purpose The purpose of the study was to conduct a systematic evaluation of the different general prescribed drugs for  premature ejaculation ( PE ) .
Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies.
PURPOSE We evaluate the efficacy of paroxetine hydrochloride as needed for the treatment of premature ejaculation . MATERIAL S AND METHOD Study 1 comprised 26 potent men with a mean age of 39.5 years with premature ejaculation who were r and omized to receive 20 mg . oral paroxetine ( group A ) or placebo ( group B ) as needed 3 to 4 hours before planned intercourse in a controlled single-blind crossover trial . Study 2 comprised 42 potent men with a mean age of 40.5 years with premature ejaculation who were r and omized to receive 10 mg . paroxetine daily for 3 weeks and then 20 mg . paroxetine as needed ( group C ) for 4 weeks or placebo daily for 3 weeks and then placebo as needed ( group D ) for 4 weeks . RESULTS Mean pretreatment ejaculatory latency time was 0.3 minute for study 1 . At 4 weeks mean ejaculatory latency time was 3.2 minutes in the paroxetine as needed and 0.45 in the placebo as needed phase for group A ( p < 0.001 ) , and 0.6 in the placebo as needed and 3.5 in the paroxetine as needed phase for group B ( p < 0.001 ) . There were no adverse effects with paroxetine or placebo in study 1 . Mean pretreatment ejaculatory latency time was 0.5 minute for study 2 . At 3 weeks mean ejaculatory latency time was 4.3 minutes in the paroxetine daily and 5.8 in the paroxetine as needed phase , and 0.9 in the placebo daily and 0.6 in the placebo as needed phase for group C ( p < 0.001 ) . At 3 weeks mean ejaculatory latency time was 0.8 minutes in the placebo daily and 1.1 in the placebo as needed phase , and 3.3 in the paroxetine daily and 6.1 in the paroxetine as needed phase for group D ( p < 0.001 ) . Adverse effects in 7 of 42 men ( 17 % ) given paroxetine daily included an ejaculation in 3 , anorexia in 1 , gastrointestinal upset in 3 and reduced libido in 2 . Mean ejaculatory latency time was greater in the paroxetine as needed phase of study 2 than that of study 1 ( p < 0.05 ) , suggesting that ejaculatory control achieved with paroxetine as needed is significantly better if patients are initially treated with the drug daily . CONCLUSIONS Paroxetine appears to be superior to placebo in the pharmacological treatment of premature ejaculation when administered on a chronic or as needed basis
Pooled evidence suggested that topical anaesthetic creams ( TAs ) , tramadol , selective serotonin reuptake inhibitors ( SSRIs ) , and phosphodiesterase type 5 inhibitors ( PDE5is ) are more effective at prolonging IELT comparing with placebo .
Conclusions We recommend the initial use of dapoxetine 30 mg OD for PE because it has been tested in largest and better design ed clinical trials rather than it is more effective than the other drugs studied .
TAs and tramadol 50 mg OD can be used as a viable alternative to oral treatment with SSRIs .
PDE5is combined with SSRIs are more effective than SSRIs monotherapy but are also associated with more side effects .
Purpose The purpose of the study was to conduct a systematic evaluation of the different general prescribed drugs for  premature ejaculation ( PE ) .